Firms Ask If DDMAC Will Assess Early Promo Claims Under TPP Guidance
Executive Summary
FDA's draft guidance directing sponsors to present proposed promotional claims in a "Target Product Profile" at the beginning of the drug development process does not address how the Division of Drug Marketing, Advertising, and Communications would be involved in the process
You may also be interested in...
Complete Submissions Are Key To Good Review Management Principles – FDA
As FDA rolls out its Good Review Management Principles - its attempt to improve FDA's timely review of drug applications through professional best practices - the agency is stressing the importance of sponsors submitting complete applications to facilitate this process
Complete Submissions Are Key To Good Review Management Principles – FDA
As FDA rolls out its Good Review Management Principles - its attempt to improve FDA's timely review of drug applications through professional best practices - the agency is stressing the importance of sponsors submitting complete applications to facilitate this process
Complete Submissions Are Key To Good Review Management Principles – FDA
As FDA rolls out its Good Review Management Principles – its attempt to improve FDA’s timely review of drug applications through professional best practices – the agency is stressing the importance of sponsors submitting complete applications to facilitate this process.